Influenza and the pandemic threat

Singapore Medical Journal

Volumn 47, Issue 6, 2006, Pages 463-469

  Lee, Vernon J ^a,c   Fernandez, G G ^a   Chen, M I ^a   Lye, D ^b   Leo, Y S ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b Department of Infections Diseases ^*

^c NATIONAL CENTRE FOR INFECTIOUS DISEASES   (Singapore)

Author keywords

Epidemiology; Infectious disease; Influenza; Pandemic

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ABSENTEEISM; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; EPIDEMIC; HOSPITALIZATION; HUMAN; HYGIENE; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; MORTALITY; NONHUMAN; PATHOGENESIS; REVIEW; SINGAPORE; UNSPECIFIED SIDE EFFECT; VACCINATION; VIROLOGY; VIRUS INFECTIVITY; WITHDRAWAL SYNDROME;

ANTIVIRAL AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COST OF ILLNESS; DISEASE OUTBREAKS; HEALTH PLANNING GUIDELINES; HUMANS; INFECTION CONTROL; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; SINGAPORE; SOCIOECONOMIC FACTORS; UNITED STATES; VIRAL VACCINES; WORLD HEALTH ORGANIZATION;

EID: 33745178804     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Ng TP, Pwee TH, Niti M, Goh LG. Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singapore 2002; 31:182-8.
2. Simonsen L, Clarke MJ, Schonberger LB, et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998; 178:53-60.
3. Information About Influenza Pandemics. Centres for Disease Control. Available at: www.cdc.gov/flu/avian/gen-info/pandemics. htm. Accessed July 14, 2005.
4. Ten things you need to know about pandemic influenza. World Oct 14, 2005. Available at: www.who.int/csr/disease/influenza/pandemic10things/en/index.html. Accessed November 10, 2005.
5. Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford: Blackwell Science, 1998.
6. Fouchier RA, Munster V, Wallensten A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 2005; 79:2814-22.
7. Reid AH, Taubenberger JK. The origin of the 1918 pandemic influenza virus: a continuing enigma. J Gen Virol 2003; 84:2285-92.
8. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362:1733-45.
9. Kida H, Ito T, Yasuda J, et al. Potential for transmission of avian influenza viruses to pigs. J Gen Virol 1994; 75:2183-8.
10. Takeda M, Pekosz A, Shuck K, Pinto LH, Lamb RA. Influenza A virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 2002; 76:1391-9.
11. Webster RG, Sharp GB, Claas EC. Interspecies transmission of influenza viruses. Am J Respir Crit Care Med 1995; 152:25-30.
12. Bean WJ, Schell M, Katz J, et al. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol 1992; 66:1129-38.
13. Taubenberger JK, Reid AH, Lourens RM, et al. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437:889-93.
14. Comment in: Nature 2005; 437:794-5.
15. Cate TR. Clinical manifestations and consequences of influenza. Am J Med 1987; 82:15-9.
16. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003; 37:1094-101.
17. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. N Engl J Med 2005; 353:1374-85.
18. Erratum in: N Engl J Med 2006; 354:884.
19. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1-40.
20. Erratum in: MMWR Morb Mortal Wkly Rep 2005; 54:750.
21. Nguyen-Van-Tam J, Granfield R, Pearson J, Fleming D, Keating N. Do influenza epidemics affect patterns of sickness absence among British hospital staff? Infect Control Hosp Epidemio 1999; 20:691-4.
22. Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987; 77:712-6.
23. Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7:1-182.
24. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev 1996; 18:64-76.
25. Kadri ZN. An outbreak of "Hong Kong Flu" in Singapore. Singapore Med J 1970; 11:30-2.
26. Doraisingham S, Goh KT, Ling AE, Yu M. Influenza surveillance in Singapore: 1972-86. Bull World Health Organ 1988; 66:57-63.
27. Chew FT, Doraisingham S, Ling AE, Kumarasinghe G, Lee BW. Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect 1998; 121:121-8.
28. Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004; 159:623-33.
29. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 2004; 432:904-6.
30. Comment in: Naure 2004; 432:817.
31. Yin-Coggrave M, Kadri ZN. Type B influenza in Singapore. Singapore Med J 1965; 79:71-4.
32. Chiu SS, Tse CY, Lau YL, Peiris M. Influenza A infection is an important cause of febrile seizures. Pediatrics 2001; 108:63.
33. Comment in: Pediatrics 2001; 108:1004-5.
34. Swee YO, Dourado H. Influenza epidemic in Singapore children: clinical impressions. Br Med J 1957; 29:1523-5.
35. Lee VJ, Phua KH, Chen MI, et al. Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore. Emerg Infect Dis 2006; 12:95-102.
36. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160:3243-7.
37. Govaert TM, Dinant GJ, Aretz K, Knottnerus JA. The predictive value of influenza symptomatology in elderly people. Fam Pract 1998; 15:16-22.
38. Storch GA. Rapid diagnostic tests for influenza. Curr Opin Pediatr 2003; 15:77-84.
39. Ng EK, Cheng PK, Ng AY, Hoang TL, Lim WW. Influenza A H5N1 detection. Emerg Infect Dis 2005; 11:1303-5.
40. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998; 48:85-90.
41. Ministry of Health, Singapore. Hospital Bill Size 2004. Available at: www.moh.gov.sg/corp/charges/common/billsize.do?id=22 Accessed March 20, 2005.
42. Viboud C, Boelle PY, Pakdaman K, et al. Influenza epidemics in the United States, France, and Australia, 1972-1997. Em erg Infect Dis 2004; 10:32-9.
43. Luk J, Gross P, Thompson WW. Observations on mortality during the 1918 influenza pandemic. Clin Infect Dis 2001; 33:1375-8.
44. Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. World Health Organization International Avian Influenza Investigative Team. N Engl J Med 2004; 350:1179-88.
45. Comment in: N Engl J Med 2004; 350:1171-2.
46. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999; 5:659-71.
47. Williams JR, Chen PY, Cho CT, Chin TD. Influenza: prospect for prevention and control. Kaohsiung J Med Sci 2002; 18:421-34.
48. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003; 21:1776-19.
49. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:1175-81.
50. Comment in: Lancet 2005; 366:1139-40.
51. United States Centers for Disease Control and Prevention. CDC Health Alert, Jan 14, 2006. CDC Recommends against the Use of Amantadine and Rimandatine for the Treatment or Prophylaxis of Influenza in the United States during the 2005-06 Influenza Season. Available at: www. cdc.gov/flu/han011406. htm. Accessed January 15, 2006.
52. Aoki FY, Macleod MD, Paggiaro P, et al. IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-9.
53. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-73.
54. Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:1235.
55. Comment in: BMJ 2003; 327:105-6,
56. BMJ 2003; 326:1223-4,
57. BMJ 2003; 328:227.
58. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355:1845-50.
59. Erratum in: Lancet 2000; 356:1856.
60. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352:1877-81.
61. Erratum in: Lancet 1999; 353:504, 1104.
62. Comment in: Lancet 1998; 352: 1872-3,
63. Lancet 1999; 353:668-9.
64. Bowles SK, Lee W, Simor AE, et al. Oseltamivir Compassionate Use Program Group. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002; 50:608-16.
65. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-72.
66. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43:1616-20.
67. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001; 45:2723-32.
68. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000; 48:101-15.
69. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med 2005; 4:107-16.
70. Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 2001; 45:1216-24.
71. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-72.
72. Comment in: N Engl J Med 2005; 353:2633-6,
73. N Engl J Med 2005; 354:1423-4.
74. Balicer RD, Huerta M, Davidovitch N, Grotto I. Cost-benefit of stockpiling drugs for influenza pandemic. Emerg Infect Dis 2005; 11:1280-2.
75. Gani R, Hughes H, Fleming D, et al. Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis 2005; 11:1355-62.
76. Cinti S, Chenoweth C, Monto AS. Preparing for pandemic influenza: should hospitals stockpile oseltamivir? Infect Control Hosp Epidemiol 2005; 26:852-4.
77. World Health Organization. Responding to the avian influenza pandemic threat. Recommended strategic actions. Available at: www.who.int/csr/resources/ publications/influenza/WHO_CDS_ CSR_GIP_05_8-EN.pdf. Accessed November 20, 2005.
78. World Health Organization Writing Group. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis 2005; 12: 81-7.
79. World Health Organization Writing Group. Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis 2005; 12:88-94.
80. United States Centers for Disease Control and Prevention. Guidelines and Recommendations. Updated Infection Control Measures for the Prevention and Control of Influenza in Health-Care Facilities. January 20, 2005. Available at: www.cdc.gov/flu/professionals/infectioncontrol/healthcarefacilities.htm. Accessed November 20, 2005.
81. The World Health Organization. WHO guidelines on the use of vaccines and antivirals during influenza pandemics. Geneva, Word Health Organization, 2004. Available at: www.who.int/csr/resources/publications/influenza/11_29_01_A.pdf. Accessed March 23, 2006.
82. United States Centers for Disease Control and Prevention. Guidelines and Recommendations. Interim Guidance for the Use of Masks to Control Influenza Transmission. August 8, 2005. Available at: www.cdc.gov/flu/professionals/ infectioncontrol/maskguidance.htm. Accessed November 20, 2005.
83. United States Centers for Disease Control and Prevention. Interim Recommendations for Infection Control in Health-Care Facilities Caring for Patients with Known or Suspected Avian Influenza. May 21, 2004. Available at: www.cdc.gov/flu/avian/professional/infectcontrol.htm. Accessed November 20, 2005.
84. Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. Lancet Infect Dis 2002; 2:145-55.
85. Erratum in: Lancet Infect Dis 2002; 2:383.